We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Newly Created Prion Seen As Exciting Research Tool

By LabMedica International staff writers
Posted on 20 Jun 2018
Print article
Image: Synthetic human prions accumulating in the brain of humanized transgenic mice (Photo courtesy of Case Western Reserve University School of Medicine).
Image: Synthetic human prions accumulating in the brain of humanized transgenic mice (Photo courtesy of Case Western Reserve University School of Medicine).
A neurodegenerative disease research team has created an exciting new research tool by synthesizing a fully functional, infectious human prion, similar to that causing the fatal progressive neural disorder Creutzfeldt-Jakob disease.

Heretofore, attempts to generate infectious synthetic human prions have not yet been successful, blocking the pathway to comprehensive understanding of human prion diseases such as sporadic Creutzfeldt-Jakob disease (sCJD).

In the June 4, 2018, online edition of the journal Nature Communications, investigators at the Case Western Reserve University School of Medicine (Cleveland OH, USA) described studies conducted to repair this lack, by showing that human prions could be synthesized in vitro from bacterially expressed recombinant human PrP (prion protein) in a reaction seeded with sCJD MM1 prions in the presence of a novel cofactor, ganglioside GM1.

The investigators reported that the synthetic human prions that they had made were infectious to transgenic mice expressing non-glycosylated human prion protein, causing neurologic dysfunction after 459 and 224 days in the first and second passage, respectively. The neuropathology, replication potency, and biophysical profiling suggested that a novel, particularly neurotoxic human prion strain had been created.

By comparing the structural organization of these synthetic human prions with that of parent sCJD MM1 prions and noninfectious human prion protein amyloid, the investigators identified domains in PrP that were important for the initiation of replication in vivo, i.e. their infectivity, and for targeting of different anatomical brain structures.

“This accomplishment represents a watershed,” said senior author Dr. Jiri G. Safar, professor of pathology and neurology at the Case Western Reserve School of Medicine. “Until now our understanding of prions in the brain has been limited. Being able to generate synthetic human prions in a test tube as we have done will enable us to achieve a much richer understanding of prion structure and replication. This is crucial for developing inhibitors of their replication and propagation throughout the brain, which is essential for halting prion-based brain disease.”

“Our findings explain at the structural level the emergence of new human prions and provide a basis for understanding how seemingly subtle differences in misfolded protein structure and modifications affect their transmissibility, cellular targeting, and thus manifestation in humans,” said Dr. Safar.

Related Links:
Case Western Reserve University School of Medicine

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
HbA1c Test
HbA1c Rapid Test
New
Alpha-Fetoprotein Reagent
AFP Reagent Kit

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.